Wu Suhui, Lian Junfang, Tao Huijuan, Shang Haixia, Zhang Li
Department of Gynecology, the First Hospital, Shanxi Medical University, Taiyuan 030001, P.R. China.
Oncol Lett. 2011 Nov;2(6):1261-1267. doi: 10.3892/ol.2011.409. Epub 2011 Sep 2.
Associations of functional single nucleotide polymorphisms in MIF-173G/C with early stage cervical cancer were investigated in a hospital-based case-control study on 250 patients with cervical cancer prior to surgery (including 49 cases with and 201 cases without lymphatic metastasis) and 147 healthy controls. The polymorphism was assessed using restriction fragment length polymorphism polymerase chain reaction, and the MIF serum concentration was examined using the enzyme-linked immunosorbent assay to analyze the correlation between the polymorphism and the MIF serum concentration. Carriers of the variant C allele in MIF-173 were at a significantly higher risk of cervical cancer compared to carriers of the wild-type allele (aOR=1.508; 95% CI, 1.128-2.016, p=0.05). The GC and CC genotypes may be the causative factors for cervical cancer (aOR=1.851; 95% CI, 1.132-3.027, p=0.013). Individuals with the GC+CC genotype and C allele at the MIF-173G/C site were at a significantly higher risk of cervical cancer and lymphatic metastasis. The risk of lymphatic metastasis in early stage cervical cancer was increased more than 1.6 times in patients with the CC and GC genotypes compared with those with the GG genotype. The genotype distribution and allele frequency of MIF-173G/C were statistically significant in the well-, moderately and poorly differentiated groups (P<0.05). Compared to the GG genotype and G allele, patients with GC and CC genotypes and C allele exhibited a lower degree of differentiation and a higher degree of malignancy. A significant difference was observed in MIF serum concentrations among the various subgroups (P<0.05). The early cervical cancer, lymphatic metastasis and poorly differentiated groups exhibited higher MIF levels in serum. Moreover, patients with the CC genotype exhibited higher MIF serum concentration, which could increase the risk of early stage cervical cancer and lymphatic metastasis. The results presented in this study provide the first evidence that the genetic polymorphism MIF-173 is associated with cervical cancer in humans. Detection of MIF serum concentration and genotyping may be used as biomarkers for early diagnosis and therapy for cervical cancer.
在一项基于医院的病例对照研究中，对250例手术前的宫颈癌患者（包括49例有淋巴结转移和201例无淋巴结转移的患者）和147名健康对照者进行了研究，以探讨MIF - 173G/C功能单核苷酸多态性与早期宫颈癌的关联。使用限制性片段长度多态性聚合酶链反应评估该多态性，并使用酶联免疫吸附测定法检测MIF血清浓度，以分析该多态性与MIF血清浓度之间的相关性。与野生型等位基因携带者相比，MIF - 173中变异C等位基因的携带者患宫颈癌的风险显著更高（调整后比值比[aOR]=1.508；95%置信区间[CI]，1.128 - 2.016，p = 0.05）。GC和CC基因型可能是宫颈癌的致病因素（aOR = 1.851；95% CI，1.132 - 3.027，p = 0.013）。MIF - 173G/C位点具有GC + CC基因型和C等位基因的个体患宫颈癌和淋巴结转移的风险显著更高。与GG基因型患者相比，CC和GC基因型的早期宫颈癌患者发生淋巴结转移的风险增加了1.6倍以上。MIF - 173G/C的基因型分布和等位基因频率在高分化、中分化和低分化组中具有统计学意义（P < 0.05）。与GG基因型和G等位基因相比，GC和CC基因型以及C等位基因的患者分化程度较低，恶性程度较高。各亚组之间的MIF血清浓度存在显著差异（P < 0.05）。早期宫颈癌、淋巴结转移和低分化组的血清MIF水平较高。此外，CC基因型患者的MIF血清浓度较高，这可能会增加早期宫颈癌和淋巴结转移的风险。本研究结果首次证明基因多态性MIF - 173与人类宫颈癌有关。检测MIF血清浓度和基因分型可作为宫颈癌早期诊断和治疗的生物标志物。
